On October 26, 2023 Codagenix Inc., a clinical-stage synthetic biology company with a rational virus design platform for viral vaccines and immuno-oncology therapeutics, reported the presentation of preclinical data for CodaLytic, a codon-modified virus being developed for breast cancer immunovirotherapy, at the Society for the Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 38th Annual Meeting being held virtually and in-person November 1-5, 2023 in San Diego, California (Press release, Codagenix, OCT 26, 2023, View Source [SID1234636392]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"These results demonstrate that CodaLytic treatment induced tumor immune infiltration driving anti-tumor efficacy in multiple, diverse preclinical models, and underscore the potential utility of this candidate as a valuable component of novel therapeutic regimens," said Johanna Kaufmann, Ph.D., Executive Vice President of Oncology and Immunology at Codagenix. "CodaLytic is the first codon-modified virus developed by Codagenix to treat cancer, and we look forward to building upon these promising results and deepening our understanding of how this virotherapeutic candidate can support anti-tumor immunity in breast cancer patients."
Presentation Details
Title: Immunovirotherapy with the codon-modified influenza virus CodaLytic modulates the quality of the tumor immune infiltrate in support of anti-tumor immunity
Abstract Number: 1100
Date and Time: Saturday, November 4, 2023: 11:55–1:25 p.m. PDT and 7-8:30 p.m. PDT
Presenting Authors: Johanna Kaufmann, Ph.D. and Katarina Blagovic, Ph.D.